Cutaneous Squamous Cell Carcinoma Development Is Associated with a Temporal Infiltration of ILC1 and NK Cells with Immune Dysfunctions.


Journal

The Journal of investigative dermatology
ISSN: 1523-1747
Titre abrégé: J Invest Dermatol
Pays: United States
ID NLM: 0426720

Informations de publication

Date de publication:
10 2021
Historique:
received: 09 12 2020
revised: 24 02 2021
accepted: 07 03 2021
pubmed: 9 4 2021
medline: 15 12 2021
entrez: 8 4 2021
Statut: ppublish

Résumé

NK cells and tissue-resident innate lymphoid cells (ILCs) are innate effectors found in the skin. To investigate their temporal dynamics and specific functions throughout the development of cutaneous squamous cell carcinoma (cSCC), we combined transcriptomic and immunophenotyping analyses in mouse and human cSCCs. We identified an infiltration of NK cells and ILC1s as well as the presence of a few ILC3s. Adoptive transfer of NK cells in NK cell‒ and ILC-deficient Nfil3

Identifiants

pubmed: 33831432
pii: S0022-202X(21)01135-0
doi: 10.1016/j.jid.2021.03.018
pii:
doi:

Substances chimiques

Basic-Leucine Zipper Transcription Factors 0
NCR1 protein, human 0
Natural Cytotoxicity Triggering Receptor 1 0
Nfil3 protein, mouse 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2369-2379

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Carmelo Luci (C)

Molecular and Cellular Pharmacology Institute, CNRS UMR7275, Côte d'Azur University, Valbonne, France; C3M, INSERM U1065, Côte d'Azur University, Nice, France.

Franck Bihl (F)

Molecular and Cellular Pharmacology Institute, CNRS UMR7275, Côte d'Azur University, Valbonne, France.

Pierre Bourdely (P)

Molecular and Cellular Pharmacology Institute, CNRS UMR7275, Côte d'Azur University, Valbonne, France; Inflammation Biology and Cancer Immunology, Peter Gorer Department of Immunobiology, King's College London, London, United Kingdom.

Sokchea Khou (S)

Molecular and Cellular Pharmacology Institute, CNRS UMR7275, Côte d'Azur University, Valbonne, France; Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon, USA.

Alexandra Popa (A)

Molecular and Cellular Pharmacology Institute, CNRS UMR7275, Côte d'Azur University, Valbonne, France; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Medical University of Vienna, Vienna, Austria.

Aida Meghraoui-Kheddar (A)

Molecular and Cellular Pharmacology Institute, CNRS UMR7275, Côte d'Azur University, Valbonne, France.

Ophelie Vermeulen (O)

Molecular and Cellular Pharmacology Institute, CNRS UMR7275, Côte d'Azur University, Valbonne, France.

Roxane Elaldi (R)

Molecular and Cellular Pharmacology Institute, CNRS UMR7275, Côte d'Azur University, Valbonne, France; Head and Neck University Institute, Centre Antoine Lacassagne, Nice, France.

Gilles Poissonnet (G)

Head and Neck University Institute, Centre Antoine Lacassagne, Nice, France.

Anne Sudaka (A)

Pathology laboratory and Human biobank, Centre Antoine Lacassagne, Nice, France.

Alexandre Bozec (A)

Head and Neck University Institute, Centre Antoine Lacassagne, Nice, France.

Selma Bekri (S)

Molecular and Cellular Pharmacology Institute, CNRS UMR7275, Côte d'Azur University, Valbonne, France; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Julie Cazareth (J)

Molecular and Cellular Pharmacology Institute, CNRS UMR7275, Côte d'Azur University, Valbonne, France.

Gilles Ponzio (G)

Molecular and Cellular Pharmacology Institute, CNRS UMR7275, Côte d'Azur University, Valbonne, France.

Pascal Barbry (P)

Molecular and Cellular Pharmacology Institute, CNRS UMR7275, Côte d'Azur University, Valbonne, France.

Roger Rezzonico (R)

Molecular and Cellular Pharmacology Institute, CNRS UMR7275, Côte d'Azur University, Valbonne, France.

Bernard Mari (B)

Molecular and Cellular Pharmacology Institute, CNRS UMR7275, Côte d'Azur University, Valbonne, France.

Veronique M Braud (VM)

Molecular and Cellular Pharmacology Institute, CNRS UMR7275, Côte d'Azur University, Valbonne, France.

Fabienne Anjuère (F)

Molecular and Cellular Pharmacology Institute, CNRS UMR7275, Côte d'Azur University, Valbonne, France. Electronic address: anjuere@ipmc.cnrs.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH